Detalhe da pesquisa
1.
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.
Clin Cancer Res
; 27(10): 2899-2909, 2021 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33685866
2.
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
Clin Cancer Res
; 26(11): 2535-2545, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32086345
3.
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.
Cancer Discov
; 8(6): 714-729, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29650534